The actuarial follow-up period of 13 years is relatively short and few PCa-specific deaths occurred in our study population during the study period—likely owing, in part, to the lead-time bias of PSA screening on PCa-specific mortality and the treatment of diagnosed clinically significant PCa. This evidence concerns the gene KLK3 and posterior cortical atrophy.